Drug discovery is a difficult and time-consuming process that involves the identification of potent therapeutic | TECH VI EW I agents with good bioavailability, metabolic stability, and low toxicity. An important first step in this process is the identification of molecules that bind with high affinity and selectivity to the biological target. High-affinity ligands might be discovered by screening natural products or large chemical libraries. However, molecules may not exist that have functional groups in the correct spatial orientation to interact optimally with the binding site. To increase the chances of finding such a molecule, many compounds could be synthesized using recently developed approaches in combinatorial chemistry and parallel synthesis (1). Yet it is often difficult to develop the synthetic procedures required to assemble many different fragments with a variety of linkers. This may ultimately limit the diversity of the compounds that can be synthesized. Furthermore, the synthesis and testing of large numbers of molecules is both costly and time-consuming.
bound water molecules, and the use of relatively simple force fields (3). Ideally, experimental determination of the fragment molecules that bind to the protein and use of structural information to guide linker design is preferred. Toward this goal, we developed a method for producing high-affinity ligands in which small molecules that bind to proximal subsites of a protein are identified in an NMR-based screen and then linked together in their experimentally determined bound orientations ( Fig. 1) (4) . The method is called "SAR by NMR," which stands for "structure-activity relationships by nuclear magnetic resonance."
In the first step of the SAR-by-NMR method, we screen a library of small molecules for binding to (Fig. 2) . Synthesis and analysis of a real library of this size would be an arduous and costly task.
The limitations of the SARby-NMR method are that it requires highfield NMR spectrometers, large amounts of pure 15N-labeled protein (>200 mg), and biomolecular targets with a molecular mass less than 40 kD that are water soluble at concentrations of -0.2 mM. Fortunately, many proteins that serve as drug targets are small or contain small functional domains and can be overexpressed in bacteria, 15N-labeled, and prepared in sufficient quantities. For those target proteins that do not meet these criteria, we have developed 1D NMR methods that exploit the changes in relaxation or diffusion rates of small molecules that occur upon complexation (5). Because these methods depend on the detection of uncomplexed molecules rather than the 15N-labeled protein, they can be used with very large biomolecules. Furthermore, the 1D technique may be used to directly identify ligands from a complex mixture of compounds, reducing the amount of time needed for NMR-based screening. Another requirement of SAR by NMR (or any method used for detecting weakly bound ligands) is that the compounds must be soluble at millimolar concentrations in aqueous solution. This requirement is easily met, because many water-soluble compounds with diverse functional groups are available from commercial sources. Does the SAR-by-NMR method work in practice? We now have several examples that demonstrate the utility of this technique. In our first example, a molecule that binds tightly (Kd = 19 nM) to the FK506 binding protein (FKBP) was discovered by tethering two fragments that only bind weakly (Kd = 2 jM and 100 gM) to this protein (4). The two fragments were rapidly identified and optimized (less than 2 *#1 >avsvs-6 months), and only five linked molecules were synthesized. All five compounds exhibited nanomolar affinities for FKBP. The SAR-by-NMR technique was also used to discover potent, nonpeptide inhibitors of stromelysin (6). This enzyme is a member of the family of matrix metalloproteinases which, when overexpressed or disregulated, are associated with pathological conditions such as arthritis and tumor metastases. Acetohydroxamic acid and a biphenyl-containing compound were found to bind to adjacent sites on stromelysin with affinities of 17 mM and 0.02 mM, respectively. Guided by the NMR structure of two ligands bound to stromelysin, fragments were linked together to produce nanomolar inhibitors of this enzyme. Only 6 months were required for the entire process, since the chemistry was highly focused on linking together molecules that were optimized for binding to the protein. The structure-activity relationships observed for the unlinked molecules were found to correlate well with those observed for the linked compounds (6). In addition to inhibiting stromelysin, the linked compounds are potent inhibitors of gelatinase A, an enzyme that is thought to play an important role in tumor metastases (7). Thus, the inhibitors discovered using SAR by NMR (or analogs of these compounds) may prove useful in the fight against cancer. In our most recent example, an NMR-based screen was used to identify compounds that bind to the DNAbinding domain of human papillomavirus E2, a protein that is required for viral replication (8). Biphenyl and biphenyl ethers containing a carboxylic acid bind to a site near the DNA recognition helix and inhibit the binding of the E2 protein to DNA.
By combining information on the structure-activity relationships for both series of molecules, a compound was synthesized that represents a new lead for the development of an antiviral agent against the human papillomavirus. It is important to note that conventional high-throughput screening of more than 100,000 compounds against stromelysin and E2 failed to produce inhibitors with potencies better than 10 gM.
In the relatively short time since its inception, we have demonstrated that SAR by NMR is a useful method for rapidly discovering high-affinity ligands for proteins. In the future, it should be possible to extend the applicability of the technique to larger proteins and other biomolecular targets such as RNA. It may also be possible to use SAR by NMR to help overcome problems in bioavailability and metabolic stability by suggesting new fragments with improved properties as replacements for those that cause unwanted effects. Our experience indicates that SAR by NMR is emerging as a useful tool that complements existing methods for tackling the challenging problem of drug discovery. 
